Literature DB >> 30639610

Immediate unselected coronary angiography versus delayed triage in survivors of out-of-hospital cardiac arrest without ST-segment elevation: Design and rationale of the TOMAHAWK trial.

Steffen Desch1, Anne Freund2, Tobias Graf3, Stephan Fichtlscherer4, Hendrik Haake5, Michael Preusch6, Fabian Hammer7, Ibrahim Akin8, Martin Christ9, Christoph Liebetrau10, Carsten Skurk11, Stephan Steiner12, Ingo Voigt13, Roland Schmitz14, Harald Mudra15, Jakob Ledwoch16, Niels Menck17, Jan Horstkotte18, Klaus Pels19, Anna-Lena Lahmann20, Sylvia Otto21, Karsten Lenk22, Marc-Alexander Ohlow23, Christian Hassager24, Peter Nordbeck25, Uwe Zeymer26, Alexander Jobs27, Suzanne de Waha-Thiele3, Denise Olbrich28, Inke König29, Kathrin Klinge28, Holger Thiele30.   

Abstract

Patients experiencing out-of-hospital cardiac arrest (OHCA) without ST-segment elevation are a heterogenic group with a variety of underlying causes. Up to one-third of patients display a significant coronary lesion compatible with myocardial infarction as OHCA trigger. There are no randomized data on patient selection and timing of invasive coronary angiography after admission. METHODS AND
RESULTS: The TOMAHAWK trial randomly assigns 558 patients with return of spontaneous circulation after OHCA with no obvious extracardiac origin of cardiac arrest and no ST-segment elevation/left bundle-branch block on postresuscitation electrocardiogram to either immediate coronary angiography or initial intensive care assessment with delayed/selective angiography in a 1:1 ratio. The primary end point is 30-day all-cause mortality. Secondary analyses will be performed with respect to initial rhythm, electrocardiographic patterns, myocardial infarction as underlying cause, neurological outcome, as well as clinical and laboratory markers. Clinical follow-up will be performed at 6 and 12 months. Safety end points include bleeding and stroke.
CONCLUSION: The TOMAHAWK trial will address the unresolved issue of timing and general indication of angiography after OHCA without ST-segment elevation.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Year:  2018        PMID: 30639610     DOI: 10.1016/j.ahj.2018.12.005

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  5 in total

Review 1.  [ESC guidelines 2020: acute coronary syndrome without persistent ST-segment elevation : What is new?]

Authors:  Holger Thiele; Alexander Jobs
Journal:  Herz       Date:  2021-02       Impact factor: 1.443

Review 2.  [ERC guidelines 2021 on cardiopulmonary resuscitation].

Authors:  Guido Michels; Janine Pöss; Holger Thiele
Journal:  Herz       Date:  2021-11-15       Impact factor: 1.443

Review 3.  Management of Out-of-Hospital Cardiac Arrest Complicating Acute Coronary Syndromes.

Authors:  Sean M Bell; Christopher Kovach; Akash Kataruka; Josiah Brown; Ravi S Hira
Journal:  Curr Cardiol Rep       Date:  2019-11-22       Impact factor: 2.931

4.  Cost Analysis From a Randomized Comparison of Immediate Versus Delayed Angiography After Cardiac Arrest.

Authors:  Cyril Camaro; Judith L Bonnes; Eddy M Adang; Eva M Spoormans; Gladys N Janssens; Nina W van der Hoeven; Lucia S Jewbali; Eric A Dubois; Martijn Meuwissen; Tom A Rijpstra; Hans A Bosker; Michiel J Blans; Gabe B Bleeker; Rémon Baak; George J Vlachojannis; Bob J Eikemans; Pim van der Harst; Iwan C van der Horst; Michiel Voskuil; Joris J van der Heijden; Bert Beishuizen; Martin Stoel; Hans van der Hoeven; José P Henriques; Alexander P Vlaar; Maarten A Vink; Bas van den Bogaard; Ton A Heestermans; Wouter de Ruijter; Thijs S Delnoij; Harry J Crijns; Gillian A Jessurun; Pranobe V Oemrawsingh; Marcel T Gosselink; Koos Plomp; Michael Magro; Paul W Elbers; Peter M van de Ven; Jorrit S Lemkes; Niels van Royen
Journal:  J Am Heart Assoc       Date:  2022-02-23       Impact factor: 6.106

5.  Complete Revascularization and One-Year Survival with Good Neurological Outcome in Patients Resuscitated from an Out-of-Hospital Cardiac Arrest.

Authors:  Vilma Kajana; Enrico Baldi; Francesca Romana Gentile; Sara Compagnoni; Federico Quilico; Luca Vicini Scajola; Alessandra Repetto; Alessandro Mandurino-Mirizzi; Marco Ferlini; Barbara Marinoni; Maurizio Ferrario Ormezzano; Roberto Primi; Sara Bendotti; Alessia Currao; Simone Savastano
Journal:  J Clin Med       Date:  2022-08-29       Impact factor: 4.964

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.